We have previously demonstrated that six weeks of prophylaxis with interferon-alpha delays cytomegalovirus excretion and decreases viremia in recipients of kidney transplants. In a double-blind trial to evaluate the effects of a longer course of prophylaxis, we gave either 3 X 10(6) units of interferon or placebo intramuscularly to 42 patients before transplant surgery was performed. After surgery, doses were given three times a week for six weeks and then twice a week for eight weeks (total of 102 X 10(6) units). Clinical signs of cytomegalovirus infection were markedly reduced in interferon recipients. These signs developed in 7 of 22 placebo recipients and 1 of 20 interferon recipients (P = 0.03). Opportunistic superinfections (Aspergillus fumigatus and Pneumocystis carinii) occurred only in patients given placebo. Cytomegalovirus-associated glomerulopathy developed in one interferon recipient and three placebo recipients. Survival of patients and grafts was equivalent in both treatment groups, and minimal toxicity was observed with interferon. In seropositive renal-transplant recipients, interferon-alpha affords effective prophylaxis against serious cytomegalovirus infections.
This article has been cited by other articles:
Kvale, E. O., Dalgaard, J., Lund-Johansen, F., Rollag, H., Farkas, L., Midtvedt, K., Jahnsen, F. L., Brinchmann, J. E., Olweus, J.
(2006). CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood
107: 2022-2029
[Abstract][Full Text]
Griffiths, P. D.
(2002). The treatment of cytomegalovirus infection. J Antimicrob Chemother
49: 243-253
[Abstract][Full Text]
(2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother
45: 729-748
[Full Text]
Dousset, B., Conti, F., Houssin, D., Calmus, Y.
(1994). Acute Vanishing Bile Duct Syndrome after Interferon Therapy for Recurrent HCV Infection in Liver-Transplant Recipients. NEJM
330: 1160-1161
[Full Text]
Sachs, M. K.
(1992). Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine. Arch Intern Med
152: 485-501
[Abstract]
Bennett, M. A., Allen, R. D.
(1990). High-Technology Home Pharmacotherapy, II: An Overview of the Newest Home Therapies. Journal of Pharmacy Practice
3: 40-47
[Abstract]
Brayman, K. L., Dafoe, D. C., Smythe, W. R., Barker, C. F., Perloff, L. J., Naji, A., Fox, I. J., Grossman, R. A., Jorkasky, D. K., Starr, S. E., Friedman, H. M., Plotkin, S. A.
(1988). Prophylaxis of Serious Cytomegalovirus Infection in Renal Transplant Candidates Using Live Human Cytomegalovirus Vaccine: Interim Results of a Randomized Controlled Trial. Arch Surg
123: 1502-1508
[Abstract]
MEYERS, J. D., FLOURNOY, N., SANDERS, J. E., McGUFFIN, R. W., NEWTON, B. A., FISHER, L. D., LUM, L. G., APPELBAUM, F. R., DONEY, K., SULLIVAN, K. M., STORB, R., BUCKNER, C. D., THOMAS, E. D.
(1987). Prophylactic Use of Human Leukocyte Interferon After Allogeneic Marrow Transplantation. ANN INTERN MED
107: 809-816
[Abstract]
HIRSCH, M. S., KAPLAN, J. C.
(1985). Prospects of Therapy for Infections with Human T-Lymphotropic Virus Type III. ANN INTERN MED
103: 750-755
[Abstract]
